{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:01:25Z","timestamp":1786118485528,"version":"build-2736575974"},"reference-count":18,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,6,22]]},"DOI":"10.2967\/jnumed.126.272721","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:55:15Z","timestamp":1786031715000},"page":"jnumed.126.272721","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","author":[{"given":"Cl\u00e9ment","family":"Bailly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Vija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Somme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Giraudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Godbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Girault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Viala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Douillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ch\u00eane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"2026080608550742000_jnumed.126.272721v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026080608550742000_jnumed.126.272721v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026080608550742000_jnumed.126.272721v1.3","doi-asserted-by":"crossref","first-page":"102710","DOI":"10.1016\/j.fjurol.2024.102710","article-title":"French AFU Cancer Committee Guidelines\u2013update 2024\u20132026: prostate cancer\u2013management of metastatic disease and castration resistance","volume":"34","author":"Ploussard","year":"2024","journal-title":"Fr J Urol."},{"key":"2026080608550742000_jnumed.126.272721v1.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"2026080608550742000_jnumed.126.272721v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"2026080608550742000_jnumed.126.272721v1.6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and metastatic prostate cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol."},{"key":"2026080608550742000_jnumed.126.272721v1.7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2024.42.4_suppl.157","article-title":"PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA treatment [abstract]","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026080608550742000_jnumed.126.272721v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.03.015"},{"key":"2026080608550742000_jnumed.126.272721v1.9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/jco.2012.30.5_suppl.92","article-title":"Frequency and prognostic significance of the PSA flare-up phenomenon in men with castration-resistant prostate cancer undergoing docetaxel-based chemotherapy [abstract]","volume":"30","author":"Piper","year":"2012","journal-title":"J Clin Oncol."},{"key":"2026080608550742000_jnumed.126.272721v1.10","doi-asserted-by":"crossref","first-page":"1758835920987654","DOI":"10.1177\/1758835920987654","article-title":"Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging","volume":"13","author":"Conteduca","year":"2021","journal-title":"Ther Adv Med Oncol."},{"key":"2026080608550742000_jnumed.126.272721v1.11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.2024.42.4_suppl.81","article-title":"Patient characteristics, treatment patterns, and outcomes among early adopters of lutetium Lu 177 vipivotide tetraxetan ([177Lu]Lu-PSMA-617): a real-world US study [abstract]","volume":"42","author":"Wei","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026080608550742000_jnumed.126.272721v1.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267816"},{"key":"2026080608550742000_jnumed.126.272721v1.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2026080608550742000_jnumed.126.272721v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"2026080608550742000_jnumed.126.272721v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.101"},{"key":"2026080608550742000_jnumed.126.272721v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00009-9"},{"key":"2026080608550742000_jnumed.126.272721v1.17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1200\/JCO.2025.43.5_suppl.121","article-title":"Efficacy of [177Lu]Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis [abstract]","volume":"43","author":"Yazdanpanah","year":"2025","journal-title":"J Clin Oncol."},{"key":"2026080608550742000_jnumed.126.272721v1.18","unstructured":"PSMA-REACH: real-world utilization of [177Lu]Lu-PSMA-617 (Pluvicto\u00ae) in the treatment of patients with metastatic castration-resistant prostate cancer [in French]. French Health Data Hub website. https:\/\/www.health-data-hub.fr\/projets\/psma-reach-utilisation-en-vie-reelle-de-177lu-psma-617-pluvictor-dans-le-traitement-des. Accessed March 20, 2026."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:55:17Z","timestamp":1786031717000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":18,"alternative-id":["10.2967\/jnumed.126.272721"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272721","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}